Publikationen:

(Liste unvollständig)


    • Viveiros, A., B. Schaefer, H. Tilg and H. Zoller (2019). „Iron Matryoshka-Haemochromatosis nested in Ferroportin Disease?“ Liver Int 39(6): 1014-1015.

    • Schaefer, B., H. Zoller and S. Schneeberger (2018). „Viveiros, A., A. Finkenstedt, B. Schaefer, M. Mandorfer, B. Scheiner, K. Lehner, M. Tobiasch, T. Reiberger, H. Tilg, M. Edlinger and H. Zoller (2018). „Transferrin as a predictor of survival in cirrhosis.“ Liver Transpl 24(3): 343-351.

    • Schaefer, B., H. Zoller and S. Schneeberger (2018). „Con: Liver transplantation for expanded criteria malignant diseases.“ Liver Transpl 24(1): 104-111.

    • Schaefer, B., A. Viveiros, R. Al-Zoairy, S. Blach, S. Brandon, H. Razavi, L. Dorn, A. Finkenstedt, M. Effenberger, I. Graziadei, M. Sarcletti, H. Tilg and H. Zoller (2018). „Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030.“ PLoS One 13(7): e0200750.

    • Schaefer, B., M. Mandorfer, A. Viveiros, A. Finkenstedt, P. Ferenci, S. Schneeberger, H. Tilg and H. Zoller (2018). „Heterozygosity for the alpha-1-antitrypsin Z allele in cirrhosis is associated with more advanced disease.“ Liver Transpl 24(6): 744-751.

    • Viveiros, A., B. Schaefer, H. Tilg and H. Zoller (2019). „Iron Matryoshka-Haemochromatosis nested in Ferroportin Disease?“ Liver Int 39(6): 1014-1015.

    • Zoller, H., B. Schaefer and B. Glodny (2017). „Iron-induced hypophosphatemia: an emerging complication.“ Curr Opin Nephrol Hypertens 26(4): 266-275.

    • Viveiros, A., M. Reiterer, B. Schaefer, A. Finkenstedt, S. Schneeberger, H. Schwaighofer, P. Moser, R. Sprenger, B. Glodny, W. Vogel, A. R. Janecke and H. Zoller (2017). „CCBE1 mutation causing sclerosing cholangitis: Expanding the spectrum of lymphedema-cholestasis syndrome.“ Hepatology 66(1): 286-288.

    • Viveiros, A., R. Rehwald, E. Vettori, A. Finkenstedt, M. Effenberger, B. Schaefer, L. Dorn, H. Tilg, S. Schneeberger, B. Glodny, H. Zoller and M. C. Freund (2017). „Prognostic significance of hepatic arterial collaterals in liver transplant recipients with biliary strictures.“ Clin Transplant 31(2).

    • Schaefer, B., P. Wurtinger, A. Finkenstedt, V. Braithwaite, A. Viveiros, M. Effenberger, I. Sulzbacher, A. Moschen, A. Griesmacher, H. Tilg, W. Vogel and H. Zoller (2016). „Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk.“ PLoS One 11(12): e0167146.

    • Finkenstedt, A., A. Vikoler, M. Portenkirchner, K. Mulleder, M. Maglione, C. Margreiter, P. Moser, W. Vogel, R. Bale, M. Freund, A. Luger, H. Tilg, J. Petersen, S. Schneeberger, I. Graziadei, H. Zoller and B. Glodny (2016). „Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy.“ Liver Int 36(5): 688-695.

    • Schaefer B, Haschka D, Finkenstedt A, et al. Impaired hepcidin expression in alpha-1-antitrypsin deficiency associated with iron overload and progressive liver disease. Hum Mol Genet 2015;24:6254-63.

    • Zoller, H., & Finkenstedt, A. (2014). Should C282Y homozygotes with mild iron overload be treated? J Hepatol. doi: 10.1016/j.jhep.2014.11.037

    • Schaefer, B., Steurer, M., Glodny, B., Neureiter, D., Moser, P., Dorn, L., Vogel, W., & Zoller, H. (2014). First experience with brentuximab vedotin in posttransplant lymphoproliferative disorder after liver transplantation: complete remission followed by lethal sepsis. Liver Transpl, 20(9), 1145-1148. doi: 10.1002/lt.23918

    • Schaefer, B., Effenberger, M., & Zoller, H. (2014). Iron metabolism in transplantation. Transpl Int, 27(11), 1109-1117. doi: 10.1111/tri.12374

    • Praschberger, R., Schranz, M., Griffiths, W. J., Baumgartner, N., Hermann, M., Lomas, D. J., Pietrangelo, A., Cox, T. M., Vogel, W., & Zoller, H. (2014). Impact of D181V and A69T on the function of ferroportin as an iron export pump and hepcidin receptor. Biochim Biophys Acta, 1842(9), 1406-1412. doi: 10.1016/j.bbadis.2014.05.011

    • Finkenstedt, A., Schranz, M., Bosch, S., Karall, D., Burgi, S. S., Ensinger, C., Drach, M., Mayr, J. A., Janecke, A. R., Vogel, W., Nachbaur, D., & Zoller, H. (2013). MNGIE Syndrome: Liver Cirrhosis Should Be Ruled Out Prior to Bone Marrow Transplantation. JIMD Rep, 10, 41-44. doi: 10.1007/8904_2012_199

    • Finkenstedt, A., Nachbaur, K., Zoller, H., Joannidis, M., Pratschke, J., Graziadei, I. W., & Vogel, W. (2013). Acute-on-chronic liver failure: excellent outcomes after liver transplantation but high mortality on the wait list. Liver Transpl, 19(8), 879-886. doi: 10.1002/lt.23678

    • Finkenstedt, A., Auer, C., Glodny, B., Posch, U., Steitzer, H., Lanzer, G., Pratschke, J., Biebl, M., Steurer, M., Graziadei, I., Vogel, W., & Zoller, H. (2013). Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis. Clin Gastroenterol Hepatol, 11(12), 1667-1672. doi: 10.1016/j.cgh.2013.06.025

    • Zoller, H., Schloegl, A., Schroecksnadel, S., Vogel, W., & Fuchs, D. (2012). Interferon-alpha therapy in patients with hepatitis C virus infection increases plasma phenylalanine and the phenylalanine to tyrosine ratio. J Interferon Cytokine Res, 32(5), 216-220. doi: 10.1089/jir.2011.0093

    • Zoller, H., & Knisely, A. S. (2012). Control of iron metabolism–lessons from neonatal hemochromatosis. J Hepatol, 56(6), 1226-1229. doi: 10.1016/j.jhep.2012.02.012

    • Finkenstedt, A., Widschwendter, A., Brasse-Lagnel, C. G., Theurl, I., Hubalek, M., Dieplinger, H., Tselepis, C., Ward, D. G., Vogel, W., & Zoller, H. (2012). Hepcidin is correlated to soluble hemojuvelin but not to increased GDF15 during pregnancy. Blood Cells Mol Dis, 48(4), 233-237. doi: 10.1016/j.bcmd.2012.02.001

    • Finkenstedt, A., Dorn, L., Edlinger, M., Prokop, W., Risch, L., Griesmacher, A., Graziadei, I., Vogel, W., & Zoller, H. (2012). Cystatin C is a strong predictor of survival in patients with cirrhosis: is a cystatin C-based MELD better? Liver Int, 32(8), 1211-1216. doi: 10.1111/j.1478-3231.2012.02766.x

    • Dorn, L., Finkenstedt, A., Schranz, M., Prokop, W., Griesmacher, A., Vogel, W., & Zoller, H. (2012). Immunoglobulin subclass 4 for the diagnosis of immunoglobulin subclass 4-associated diseases in an unselected liver and pancreas clinic population. HPB (Oxford), 14(2), 122-125. doi: 10.1111/j.1477-2574.2011.00413.x

    • Mayr, R., Griffiths, W. J., Hermann, M., McFarlane, I., Halsall, D. J., Finkenstedt, A., Douds, A., Davies, S. E., Janecke, A. R., Vogel, W., Cox, T. M., & Zoller, H. (2011). Identification of mutations in SLC40A1 that affect ferroportin function and phenotype of human ferroportin iron overload. Gastroenterology, 140(7), 2056-2063, 2063 e2051. doi: 10.1053/j.gastro.2011.02.064

    • Mayr, R., Janecke, A. R., Schranz, M., Griffiths, W. J., Vogel, W., Pietrangelo, A., & Zoller, H. (2010). Ferroportin disease: a systematic meta-analysis of clinical and molecular findings. J Hepatol, 53(5), 941-949. doi: 10.1016/j.jhep.2010.05.016

    • Krismer, F., Roos, J. C., Schranz, M., Graziadei, I. W., Mechtcheriakov, S., Vogel, W., Carpenter, R. H., & Zoller, H. (2010). Saccadic latency in hepatic encephalopathy: a pilot study. Metab Brain Dis, 25(3), 285-295. doi: 10.1007/s11011-010-9210-1

    • Finkenstedt, A., Wolf, E., Hofner, E., Gasser, B. I., Bosch, S., Bakry, R., Creus, M., Kremser, C., Schocke, M., Theurl, M., Moser, P., Schranz, M., Bonn, G., Poewe, W., Vogel, W., Janecke, A. R., & Zoller, H. (2010). Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation. J Hepatol, 53(6), 1101-1107. doi: 10.1016/j.jhep.2010.04.039

    • Schranz, M., Talasz, H., Graziadei, I., Winder, T., Sergi, C., Bogner, K., Vogel, W., & Zoller, H. (2009). Diagnosis of hepatic iron overload: a family study illustrating pitfalls in diagnosing hemochromatosis. Diagn Mol Pathol, 18(1), 53-60. doi: 10.1097/PDM.0b013e31817cfd4b

    • Schranz, M., Bakry, R., Creus, M., Bonn, G., Vogel, W., & Zoller, H. (2009). Activation and inactivation of the iron hormone hepcidin: Biochemical characterization of prohepcidin cleavage and sequential degradation to N-terminally truncated hepcidin isoforms. Blood Cells Mol Dis, 43(2), 169-179. doi: 10.1016/j.bcmd.2009.03.008

    • Finkenstedt, A., Bianchi, P., Theurl, I., Vogel, W., Witcher, D. R., Wroblewski, V. J., Murphy, A. T., Zanella, A., & Zoller, H. (2009). Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency. Br J Haematol, 144(5), 789-793. doi: 10.1111/j.1365-2141.2008.07535.x